Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
- Conditions
- Heart Failure
- Interventions
- Device: Sentus QP left ventricular lead
- Registration Number
- NCT02290028
- Lead Sponsor
- Biotronik SE & Co. KG
- Brief Summary
The QP ExCELs study is designed to confirm safety and efficacy of the BIOTRONIK Sentus OTW QP left ventricular leads to satisfy FDA requirements for regulatory approval of the leads in the US. The Sentus OTW QP leads received FDA approval on May 4, 2017.
Long-term safety of the BIOTRONIK Sentus OTW QP left ventricular leads will be confirmed during the ongoing post approval phase (US sites only).
A protocol update was implemented on September 6, 2019 to transition the long-term follow up for the ongoing Sentus QP Study to a new EP PASSION real-world data methodology.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2226
- Standard CRT-D indication according to clinical routine
- De novo implantation or upgrade from existing ICD or pacemaker implant utilizing a BIOTRONIK CRT-D system with IS4 LV port and Sentus QP LV lead
- Patient is able to understand the nature of the clinical investigation and provide written informed consent
- Patient is able and willing to complete all routine study visits at the investigational site through 5 years of follow-up
- Patient accepts Home Monitoring® concept
- Age ≥ 18 years
- Chronic atrial fibrillation
- Contraindication to CRT-D therapy
- Currently implanted with an endocardial or epicardial left ventricular lead or had prior attempt to place a left ventricular lead
- Cardiac surgical procedure, such as coronary artery bypass graft or valve surgery that is planned to occur within 6 months after implant or ablation that is planned to occur within 90 days after implant (ablations planned to occur prior to or at implant are not exclusionary)
- Expected to receive a heart transplant or ventricular assist device within 6 months
- Life expectancy less than 12 months
- Participation in any other investigational cardiac clinical investigation during the course of the study
- Presence of another life-threatening, underlying illness separate from their cardiac disorder
- Pregnant or breast-feeding at time of enrollment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Sentus QP left ventricular lead Sentus QP left ventricular lead Subjects consented and implanted with a Sentus QP left ventricular lead.
- Primary Outcome Measures
Name Time Method Sentus QP Related Complication-free Rate Up to 4 years The purpose of primary endpoint 3 is to evaluate the Sentus QP related complication-free rate through study termination (post approval phase). This is evaluated as a percentage of participants without a complication.
Percentage of Participants With Acceptable Pacing Threshold of Sentus QP Lead in Permanently Programmed Vector at 3 Months 3 months The purpose of primary endpoint 2 is to evaluate the LV lead pacing threshold for the permanently programmed pacing vector at 3 months post-implant.This was evaluated by performing an exact, binomial test comparing the percentage of participants with acceptable pacing thresholds to a performance goal of 88%. LV threshold values of less than or equal to 2.5 V at 0.4 ms in the permanently programmed vector are considered acceptable.
Sentus QP Related Complication-free Rate Through 6 Months 6 months The purpose of primary endpoint 1 is to evaluate the Sentus QP related complication-free rate through 6 months post-implant. This is evaluated as a percentage of participants without a complication.
- Secondary Outcome Measures
Name Time Method Sentus QP Acceptable Pacing Threshold in Novel Vectors at 3 Months 3 months The purpose of this secondary endpoint is to evaluate the number of participants with at least one acceptable LV lead pacing threshold in a novel pacing vector at 3 months post-implantation. This was evaluated as the number of participants with at least one acceptable LV pacing threshold in a novel pacing vector out of the total number of participants with completed novel pacing threshold testing. LV threshold values of less than or equal to 2.5 V at 0.4 ms in a novel pacing vector is considered acceptable.
Sentus QP Acceptable R-wave Sensed Amplitude at 3 Months Per Lead Model 3 months The purpose of this secondary endpoint is to evaluate acceptable LV lead sensing amplitude at 3 months post-implantation. This was evaluated as the number of participants with an acceptable LV sensing amplitude out of the total number of participants. R-wave sensed mean amplitude of greater than or equal to 2 mV is considered acceptable.
Sentus QP Acceptable Pacing Threshold in Permanently Programmed Vector at 3 Months Per Lead Model 3 months The purpose of the secondary endpoint is to evaluate the LV lead pacing threshold for the permanently programmed pacing vector at 3 months post-implantation in the two different lead types, Sentus OTW QP L and Sentus OTW QP S. This was evaluated as the number of participants with an acceptable pacing threshold out of the total number of patients for each lead model. LV threshold values of less than or equal to 2.5 V at 0.4 ms in the permanently programmed vector is considered acceptable.
Sentus QP Time to Complication 6 months The purpose of this secondary is to evaluate the Sentus related complication-free rate through 6 months post-implant by the Kaplan-Meier method. The below table shows Kaplan-Meier estimates of the estimated freedom from Sentus related complications at 180 days.
Number of Participants Successfully Reprogrammed to Resolve Phrenic Nerve Stimulation or High Pacing Threshold 12 months The purpose of this secondary endpoint is to evaluate the number of participants in whom phrenic nerve stimulation or high LV pacing threshold was be successfully resolved by reprogramming of the LV pacing vector. This is evaluated as the number of participants with successful reprogramming out of all participants experiencing phrenic nerve stimulation or high LV pacing threshold. LV pacing threshold resulting in invasive intervention, or, in the absence of intervention, a lead threshold that has increased two fold from the chronic threshold value, and is unable to achieve a 2:1 safety margin at follow-up is considered a high LV pacing threshold.
Sentus QP Acceptable Pacing Impedance at 3 Months Per Lead Model 3 months The purpose of this secondary endpoint is to evaluate the acceptable LV lead pacing impedance at 3 months post-implantation. This was evaluated as the number of participants with an acceptable LV pacing impedance out of the total participants. LV impedance values of greater than 200 Ohms and less than 2000 Ohms is considered acceptable.
Sentus QP Related Complication-free Rate Per Lead Model Up to 4 years The purpose of secondary endpoint 7 is to evaluate the Sentus QP related complication-free rate through study termination (post approval phase). This is evaluated as percentage of participants without a complication per lead model.
Individual Sentus QP Adverse Event Rates Up to 4 years The purpose of secondary endpoint 8 is to evaluate the rate of individual types of adverse events related to the Sentus QP lead through study termination (post approval phase). This is evaluated as the percentage of participants with a specific adverse event out of the total participants.
Trial Locations
- Locations (44)
AKH Linz
🇦🇹Linz, Austria
Royal Hobart Hospital
🇦🇺Hobart, Australia
Nambour General Hospital
🇦🇺Nambour, Australia
Flinders Medical Center
🇦🇺Bedford Park, Australia
Maria Heimsuchung Caritas Klinik Pankow
🇩🇪Berlin, Germany
Virchow Klinikum
🇩🇪Berlin, Germany
AKH Wien
🇦🇹Wien, Austria
Lyell McEwing Hospital
🇦🇺Elizabeth Vale, Australia
DHZ Berlin
🇩🇪Berlin, Germany
The Northern Hospital
🇦🇺Epping, Australia
Immanuel Klinikum Herzzentrum Bernau
🇩🇪Bernau, Germany
Städtisches Krankenhaus Bielefeld Mitte
🇩🇪Bielefeld, Germany
Heinrich Heine University Düsseldorf
🇩🇪Düsseldorf, Germany
Semmelweis University
🇭🇺Budapest, Hungary
SBK Villingen Schwenningen
🇩🇪Villingen, Germany
Universitätsklinik Erlangen
🇩🇪Erlangen, Germany
SHG-Kliniken Völklingen
🇩🇪Völklingen, Germany
UHZ Freiburg
🇩🇪Freiburg, Germany
SRH Wald-Klinikum Gera gGmbH
🇩🇪Gera, Germany
UKSH Campus Lübeck
🇩🇪Lübeck, Germany
Marienhospital Lünen
🇩🇪Lünen, Germany
Elbekliniken Stade - Buxtehude
🇩🇪Stade, Germany
Kantonspital Luzern
🇨🇭Luzern, Switzerland
Hospital Ramón y Cajal Madrid
🇪🇸Madrid, Spain
HBK Zwickau
🇩🇪Zwickau, Germany
Nusch
🇸🇰Bratislava, Slovakia
Vusch East Slovak Cardiology Institute
🇸🇰Kosice, Slovakia
University Hospital Zürich
🇨🇭Zürich, Switzerland
Barzilai Medical Center
🇮🇱Ashkelon, Israel
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Gentofte Hospital
🇩🇰Hellerup, Denmark
Odense Universitets Hospital
🇩🇰Odense, Denmark
Spedali Civili di Brescia
🇮🇹Brescia, Italy
Azienda Ospedaliero Sant'Anna Como
🇮🇹Como, Italy
Augusta-Kranken-Anstalt Bochum
🇩🇪Bochum, Germany
Augusta Krankenhaus Düsseldorf
🇩🇪Düsseldorf, Germany
Elisabeth Krankenhaus Essen
🇩🇪Essen, Germany
Westpfalzklinikum
🇩🇪Kaiserslautern, Germany
Städtisches Klinikum St. Georg
🇩🇪Leipzig, Germany
Universitätsklinikum Würzburg
🇩🇪Würzburg, Germany
Klinikum Wels-Grieskirchen GmbH
🇦🇹Wels, Austria
Soroka Medical Center
🇮🇱Beer Sheva, Israel
Rambam Medical Center
🇮🇱Haifa, Israel
Hospital Clinic Provincial de Barcelona
🇪🇸Barcelona, Spain